Being Efficient About Efficacy Estimation

Statistics in Biopharmaceutical Research

Volumn 5, Issue 3, 2013, Pages 204-210

  Senn, Stephen ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Analysis of covariance; Dichotomies; Flexible designs; Patient by treatment interaction; Pharmacogentics; Responder analysis

Indexed keywords

ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; ARTICLE; BAYES THEOREM; DRUG EFFICACY; LOG RANK TEST; MODEL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; SAMPLE SIZE; SEQUENTIAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICS;

EID: 84884298857     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2012.754726     Document Type: Article

References (47)

1. Bacchetti, P., McCulloch, C. E. and Segal, M. R. 2008. "Simple, Defensible Sample Sizes Based on Cost Efficiency" (with discussion). Biometrics, 64: 577 - 594.
2. Bauer, P. and Kohne, K. 1994. Evaluation of Experiments With Adaptive Interim Analyses. Biometrics, 50: 1029 - 1041.
3. Burman, C. F. and Sonesson, C. 2006. "Are Flexible Designs Sound?" (with discussion). Biometrics, 62: 664 - 683.
4. Collett, D. 2003. Modelling Survival Data in Medical Research, 2nd ed., Boca Raton, FL: Chapman & Hall/CRC.
5. Committee for Medicinal Products for Human Use. 2007. "Guideline on Clinical Medicinal Products Intended for the Treatment of Neuropathic Pain,", London: European Medicines Agency.
6. Fedorov, V., Mannino, F. and Zhang, R. 2009. Consequences of Dichotomization. Pharmaceutical Statistics, 8: 50 - 61.
7. Fisher, L. D. 1998. Self-Designing Clinical Trials. Statistics in Medicine, 17: 1551 - 1562.
8. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. and PhRMA Working Group. 2006. Adaptive Designs in Clinical Drug Development-An Executive Summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics, 16: 275 - 283. discussion 285-291, 293-278, 311-272
9. Helsel, D. R. 2005. Nondetects and Data Analysis: Statistics for Censored Environmental Data, Hoboken, NJ: Wiley.
10. Hung, H. M., O'Neill, R. T., Wang, S. J. and Lawrence, J. 2006. A Regulatory View on Adaptive/Flexible Clinical Trial Design. Biometrical Journal Biometrische Zeitschrift, 48: 565 - 573.
11. International Conference on Harmonisation. 1999. Statistical Principles for Clinical Trials (ICH E9). Statistics in Medicine, 18: 1905 - 1942.
12. Ioannidis, J. P. 2008. Why Most Discovered True Associations Are Inflated. Epidemiology, 19: 640 - 648.
13. ---. 2005. Why Most Published Research Findings Are False. PLoS Medicine, 2: 696 - 701.
14. Lesko, L. J. and Woodcock, J. 2004. Translation of Pharmacogenomics and Pharmacogenetics: A Regulatory Perspective. Nature Reviews Drug Discovery, 3: 763 - 769.
15. Lewis, J. A. 1983. Clinical Trials-Statistical Developments of Practical Benefit to the Pharmaceutical Industry. Journal of the Royal Statistical Society, Series A, 146: 362 - 393.
16. Lewis, J. A. 2004. In Defence of the Dichotomy. Pharmaceutical Statistics, 3: 77 - 79.
17. Lewis, J. A., Jones, D. R. and Röhmel, J. 1995. Biostatistical Methodology in Clinical Trials-A European Guideline. Statistics in Medicine, 14: 1655 - 1657.
18. Mehrotra, D. V. and Fan, X. 2006. "Adaptive vs. Group Sequential Self-Designing Trials" (with discussion). Biometrical Journal Biometrische Zeitschrift, 48: 710 - 713.
19. O'Neill, R. T. 1991. " The Biometrical Role in United States Drug Regulation ". In Biometri in Der Chemisch-Pahramzuetischen Industrie, Edited by: Vollmar, J. 31 - 42. Stuttgart: Gustav Fischer.
20. ---. 2006. FDA's Critical Path Initiative: A Perspective on Contributions of Biostatistics. Biometrical Journal Biometrische Zeitschrift, 48: 559 - 564.
21. Peck, C. C., Sheiner, L. B., Martin, C. M., Combs, D. T. and Melmon, K. L. 1973. Computer-Assisted Digoxin Therapy. New England Journal of Medicine, 289: 441 - 446.
22. Pocock, S., Altman, D., Armitage, P., Ashby, D., Bland, M., Chilvers, C., Dawid, P., Ebbutt, A., Evans, S., Finney, D., Gardner, M., Gore, S., Jones, D., Lewis, J., Machin, D., Matthews, J., Spiegelhalter, D., Sutherland, I. and Thompson, S. 1991. Statistics and Statisticians in Drug Regulation in the United Kingdom. Journal of the Royal Statistical Society, Series A, 154: 413 - 419.
23. Pocock, S. J. and White, I. 1999. "Trials Stopped Early: Too Good to Be True?" (comment). Lancet, 353: 943 - 944.
24. Proschan, M. A. and Hunsberger, S. A. 1995. Designed Extension of Studies Based on Conditional Power. Biometrics, 51: 1315 - 1324.
25. Racine, A., Grieve, A. P., Fluhler, H. and Smith, A. F.M. 1986. Bayesian Methods in Practice-Experiences in the Pharmaceutical Industry. Journal of the Royal Statistical Society, 35: 93 - 150. Series C
26. Senn, S. J. 1992. Is the 'Simple Carry-Over' Model Useful?. Statistics in Medicine, 11: 715 - 726.
27. Senn, S. J. 1998. "Applying Results of Randomised Trials to Patients. N of 1 Trials Are Needed" (letter; comment),. British Medical Journal, 317: 537 - 538.
28. Senn, S. J. 2000. "Consensus and Controversy in Pharmaceutical Statistics" (with discussion),. The Statistician, 49: 135 - 176.
29. Senn, S. J. 2001. Individual Therapy: New Dawn or False Dawn. Drug Information Journal, 35: 1479 - 1494.
30. Senn, S. J. 2003. Disappointing Dichotomies. Pharmaceutical Statistics, 2: 239 - 240.
31. Senn, S. J. 2004a. Added Values: Controversies Concerning Randomization and Additivity in Clinical Trials. Statistics in Medicine, 23: 3729 - 3753.
32. Senn, S. J. 2004b. Individual Response to Treatment: Is It a Valid Assumption?. British Medical Journal, 329: 966 - 968.
33. Senn, S. J. 2005. An Unreasonable Prejudice Against Modelling?. Pharmaceutical Statistics, 4: 87 - 89.
34. Senn, S. J. 2007. Statistical Issues in Drug Development, Hoboken, NJ: Wiley.
35. Senn, S. J. 2010. Statisticians and Pharmacokineticists: What They Can Still Learn From Each Other. Clinical Pharmacology & Therapeutics, 88: 328 - 334.
36. Senn, S. J. 2011. U Is for Unease: Reasons to Mistrust Overlap Measures in Clinical Trials. Statistics in Biopharmaceutical Research, 3: 302 - 309.
37. Senn, S. J. and Julious, S. 2009. Measurement in Clinical Trials: A Neglected Issue for Statisticians?. Statistics in Medicine, 28: 3189 - 3209.
38. Sheiner, L. B. 1991. "The Intellectual Health of Clinical Drug Evaluation" (comment). Clinical Pharmacology & Therapeutics, 50: 4 - 9.
39. Sheiner, L. B., Rosenberg, B. and Melmon, K. L. 1972. Modelling of Individual Pharmacokinetics for Computer-Aided Drug Dosage. Computers and Biomedical Research, 5: 411 - 459.
40. Sykes, R. 1997. The Pharmaceutical Industry in the New Millennium: Capturing the Scientific Promise. Technical lecture, London: Centre for Medicines Research
41. Sykes, R. 1998. Being a Modern Pharmaceutical Company Involves Making Information Available on Clinical Trial Programmes. British Medical Journal, 317: 1172
42. Tsiatis, A. A. 2006. "Information-Based Monitoring of Clinical Trials" (with discussion). Statistics in Medicine, 25: 3236 - 3244. discussion 3320-3325, 3326-3347
43. Urquhart, J. 2002. The Odds of the Three Nons When an Aptly Prescribed Medicine Isn't Working: Non-Compliance, Non-Absorption, Non-Response. British Journal of Clinical Pharmacology, 54: 212 - 220.
44. Wang, S. J., Hung, H. M. and O'Neill, R. T. 2006. Adapting the Sample Size Planning of a Phase III Trial Based on Phase II Data. Pharmaceutical Statistics, 5: 85 - 97.
45. Wang, S. J., Hung, H. M. and O'Neill, R. T. 2009. Adaptive Patient Enrichment Designs in Therapeutic Trials. Biometrical Journal Biometrische Zeitschrift, 51: 358 - 374.
46. Wang, S. J., Hung, H. M. and O'Neill, R. T. 2011. Adaptive Design Clinical Trials and Trial Logistics Models in CNS Drug Development. European Neuropsychopharmacology, 21: 159 - 166.
47. Whitehead, J. 1997. The Design and Analysis of Sequential Trials: Revised Second Edition, Chichester: Wiley.